Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756352 · ClinicalTrials.gov registry record · Phase 2
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
A Phase 2 study, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01756352 is a Phase 2 study that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 13 participants.
The verdict
NCT01756352, a Phase 2 study, has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which we expect to obtain definitive results, and two secondary aims, under which we plan to generate preliminary data to support a future, larger project.
Interventions
- DRUG 18F-FET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756352
The ClinicalTrials.gov registry entry for NCT01756352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcelo F. Di Carli, MD, FACC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FET is the first listed.
NCT01756352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756352 about?
NCT01756352 is a clinical study titled "FET-PET for Evaluation of Response of Recurrent GBM to Avastin". Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which w...
What is the current status of trial NCT01756352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-02. Estimated completion is 2015-09-13.
What interventions are being tested in trial NCT01756352?
The interventions under investigation include: 18F-FET (DRUG).
Who is sponsoring clinical trial NCT01756352?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.